Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 13/20 | 0.59 |
| ▸ | MC5R | P33032 | 13/20 | 0.59 |
| ▸ | MC3R | P41968 | 13/20 | 0.59 |
| ▸ | MC1R | Q01726 | 12/20 | 0.59 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.58 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.56 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.56 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.54 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.54 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.54 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.54 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
| ▸ | LDLR | P01130 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23835709 | 0.93 | MC4R (0.60) | MC4RMC5RMC3RMC1RPCSK9 | |
| SCHEMBL20104581 | 0.92 | PCSK9 (0.62) | MC4RMC5RMC3RMC1RPCSK9 | |
| SCHEMBL20104588 | 0.88 | PCSK9 (0.62) | MC4RMC5RMC3RMC1RPCSK9 | |
| SCHEMBL20104590 | 0.85 | SSTR1 (0.58) | MC4RMC5RMC3RMC1RPCSK9 | |
| SCHEMBL20100616 | 0.84 | KLKB1 (0.59) | MC4RMC5RMC3RMC1RPCSK9 | |
| SCHEMBL20104643 | 0.84 | PCSK9 (0.59) | MC4RMC5RMC3RMC1RPCSK9 | |
| SCHEMBL20104593 | 0.83 | PCSK9 (0.58) | MC4RMC5RMC3RMC1RPCSK9 | |
| SCHEMBL20104592 | 0.83 | PCSK9 (0.58) | MC4RMC5RMC3RMC1RPCSK9 | |
| SCHEMBL20100614 | 0.82 | MC4R (0.57) | MC4RMC5RMC3RMC1RPCSK9 | |
| SCHEMBL29666534 | 0.81 | HDAC3 (0.61) | PCSK9CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124541-B2 | Chimeric melanocortin ligands and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20180118789-A1 | CHIMERIC MELANOCORTIN LIGANDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124541-B2 | Chimeric melanocortin ligands and methods of use thereof | MC3R, MC4R, MC1R | MC4R 2/4885MC5R 4/4885MC3R 1/4885 |
| US-20180118789-A1 | CHIMERIC MELANOCORTIN LIGANDS AND METHODS OF USE THEREOF | MC3R, MC4R, MC1R | MC4R 2/4885MC5R 4/4885MC3R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.